project id: TCGA-BLCA; case submitter id: TCGA-KQ-A41S; no matched normal low pass wgs: false; no matched normal targeted sequencing: false; no matched normal wgs: false; no matched normal wxs: false; selected normal low pass wgs: false; selected normal targeted sequencing: false; selected normal wxs: false; source center: 23; state: released; a260 a280 ratio: 1.77; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 1.52; rna integrity number: 7.6; age at index: 87; days to birth: -32041; ethnicity: not reported; gender: female; race: white; vital status: Alive; year of birth: 1924; age at diagnosis: 32041; ajcc pathologic m: MX; ajcc pathologic n: NX; ajcc pathologic stage: Stage III; ajcc pathologic t: T4a; ajcc staging system edition: 7th; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 35.0; icd 10 code: C67.4; last known disease status: not reported; morphology: 8120/3; primary diagnosis: Transitional cell carcinoma; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; site of resection or biopsy: Posterior wall of bladder; synchronous malignancy: No; tissue or organ of origin: Posterior wall of bladder; tumor grade: Not Reported; year of diagnosis: 2011; treatment or therapy: no; alcohol history: Not Reported; is ffpe: false; composition: Not Reported; initial weight: 450.0; sample id: 546e9ec3-7745-4a94-bb1d-b5f40203669a; sample submitter id: TCGA-KQ-A41S-01A; portion id: c96fdc82-44cc-4c8f-91d7-e78e80a7242d; portion submitter id: TCGA-KQ-A41S-01A-12; slide id: 59e02fbc-02ea-4c32-a7b5-b0acdd76f914; slide submitter id: TCGA-KQ-A41S-01A-01-TSA; percent lymphocyte infiltration: 5.0; percent monocyte infiltration: 0.0; percent necrosis: 0.0; percent neutrophil infiltration: 0.0; percent normal cells: 0.0; percent stromal cells: 25.0; percent tumor cells: 75.0; percent tumor nuclei: 75.0; section location: TOP;